Parambir S Dulai

Northwestern University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Spatial transcriptomics enables multiplex profiling of gene cellular expression and location within the tissue context. Although large volumes of spatial transcriptomics data have been generated, the lack of systematic curation and analysis limits biological discovery. We present Spatial transcriptOmics Analysis Resource (SOAR), a comprehensive spatial transcriptomics platform with 3461 uniformly processed samples across 13 species, 42 tissue types, and 19 different spatial transcriptomics technologies. Using SOAR, we found that CXCL16 / SPP1 macrophage polarity characterizes the coordination of immune cell polarity in the tumor microenvironment. SOAR’s integrative approach toward drug discovery revealed sirolimus and trichostatin A as potential anticancer agents targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin growth and proliferation pathway and identified Janus kinase/signal transducers and activators of transcription inhibitors for ulcerative colitis treatment. SOAR’s results demonstrate its broad application to data generated from diverse spatial technologies and pathological conditions. SOAR will support future benchmarking studies and method development, facilitating discoveries in molecular functions, disease mechanisms, and potential therapeutic targets.

Year:

2025

Introduction Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear. Objective This post-hoc analysis of the LUCENT-1 trial evaluated trends in serum and histologic eosinophils as biomarkers for early response to mirikizumab induction therapy in UC. Design Data from LUCENT-1 (NCT03518086) were analyzed to assess serum eosinophil counts and histologic eosinophil presence at baseline and week 12. Clinical response, remission, and endoscopic improvement were defined by modified Mayo score criteria. Logistic regression models, adjusted for factors including steroid use, prior biologic failure, disease severity, and albumin levels, assessed associations between baseline eosinophil levels and treatment outcomes. Results Among 928 participants, 66.6% achieved clinical response. Responders had higher baseline serum eosinophils (0.23 × 109/L vs 0.19 × 109/L, P = .001) and showed greater reductions at week 12. Elevated baseline eosinophils (≥0.57 × 109/L) were associated with higher rates of clinical response (80% vs 65.7%, aOR: 2.31, P = .013), remission (33.3% vs 25.1%, aOR: 1.91, P = .044), and endoscopic improvement (46.7% vs 33.8%, aOR: 2.33, P = .003). Reductions in histologic eosinophils were also linked to improved outcomes, especially in those with moderate/marked baseline presence. Conclusions and Relevance Baseline eosinophil levels may predict response to mirikizumab and guide early treatment decisions. These findings support a potential role for eosinophils as biomarkers in UC management.

Year:

2025

Background Fecal calprotectin (FC) and C-reactive protein (CRP) are noninvasive biomarkers used in ulcerative colitis (UC) clinical trials; however, thresholds defined as “normal” in trials may be higher than “normal” thresholds typically used in clinical practice. We assessed the relationship between FC and CRP improvement in the “normal” range across different cutoff thresholds for patients with moderately to severely active UC treated with mirikizumab. Methods Patients achieving clinical response to mirikizumab in LUCENT-1 (Weeks 0-12) proceeded to LUCENT-2 (Weeks 12-52 [52 weeks of continuous mirikizumab]). Associations between FC and CRP levels at multiple thresholds and histologic-endoscopic mucosal improvement (HEMI) and histologic-endoscopic mucosal remission (HEMR) at Weeks 12 and 52 were assessed by Fisher’s exact test. Least squares means of FC and CRP changes from baseline at Weeks 12 and 52 were calculated using analysis of covariance with HEMI or HEMR status as factors and baseline FC or CRP values as covariates. Results At Weeks 12 and 52, greater proportions of patients with FC thresholds of ≤250, ≤150, ≤100, and ≤50 µg/g, and CRP thresholds of ≤6 and ≤5 mg/L, achieved HEMI and HEMR compared with those not achieving HEMI and HEMR. Changes from baseline in FC and CRP at Week 12 and FC at Week 52 were greater in patients who achieved HEMI and HEMR compared with those not achieving these endpoints. Conclusions These results show that FC and CRP analyses may contribute to a noninvasive monitoring strategy in clinical practice. ClinicalTrials.gov numbers: NCT03518086, NCT03524092.

Year:

2025

Human tissues require a mechanism to generate durable, yet modifiable, transcriptional memories to sustain cell function across a lifetime. Previously, we demonstrated that nanoscale packing domains couple heterochromatin (cores) and euchromatin (outer zone) into unified reaction volumes that can generate transcriptional memory. In prior work, this framework demonstrated that RNA synthesis occurred within the ideal zone (intermediate density) portions of the domain. Naturally, this creates a question of where genes are positioned in relation to the packing domain architecture and which genetic material fills the domain core to sustain transcription. Here we propose that this could be solved by the encoded positioning of introns, intergenic segments, and exons as a projection of the functional packing layers of domains. This suggests that introns and intergenic segments are coupled to adjacent exons to generate coherent packing domain volumes. We illustrate how this organization would reconcile contradictions in epigenetic patterns, non-randomness in oncogenic mutations, and produce durable transcriptional memory. We conclude by showing that this genome geometry might have coincided with the rapid evolution of body-plan complexity, suggesting that chromatin geometry could be fundamental to metazoan evolution.

Year:

2025

Background The Simple Endoscopic Score for Crohn’s disease (SES-CD) and Modified Multiplier of the SES-CD (MM-SES-CD) are endoscopic scoring systems used to assess disease severity and response to therapy in CD. This study evaluates their utility at baseline in predicting endoscopic remission (ER) of the ileum and colon at week 52. Methods This post-hoc analysis of 4 clinical trials (CT-P13, UNITI, EXTEND, and SEAVUE) compared baseline scores and ER outcomes at week 52 using the SES-CD and MM-SES-CD. The area under the receiver operating characteristic curve (AUC) for each scoring system’s ability to predict week 52 ER defined by various thresholds was compared. Results A total of 667 patients were included in this analysis. At baseline, the median SES-CD score was 8.5 (IQR 5.0–15.7), and the median MM-SES-CD score was 34.8 (IQR 27.5–50.0). MM-SES-CD demonstrated consistently higher AUC values compared to SES-CD across most endpoints in ileal and colonic disease involvement. Among 519 patients with any disease in the ileum, baseline MM-SES-CD demonstrated significantly better predictive accuracy than SES-CD for week 52 SES-CD < 3 [AUC 0.75 (95% CI: 0.71–0.80) vs. 0.64 (95% CI: 0.59–0.70), P = .031]. Similar findings were observed for other definitions of ER. Among 552 participants with colonic disease involvement, baseline MM-SES-CD also demonstrated significantly greater accuracy for predicting week 52 SES-CD < 3 [AUC 0.78 (95% CI: 0.73–0.82) vs. 0.62 (95% CI: 0.57–0.66), P = .002], with similar findings across other definitions of ER assessed. Similar trends were observed across isolated ileal, ileocolonic, and isolated colonic disease. Conclusion The baseline MM-SES-CD demonstrated superior predictive ability for week 52 ER compared to SES-CD across the ileum and colon. These findings support its utility in clinical trials and in routine practice for predicting long-term treatment response.

Year:

2025

Background Despite the growing availability of advanced medical therapies for inflammatory bowel disease (IBD), significant gaps remain in treatment initiation. Targeted education and point-of-care clinical decision support may address this gap and lead to improved patient outcomes. Methods A multiphase IBD-focused provider education and decision support program spanning 10 years was developed consisting of (1) symposia-based education (n = 1101 learners; 2014 to 2019), (2) point-of-care education (n = 8547 learners) with clinical decision support tool (CDST) deployment (n = 11 940 users, n = 954 learners; 2019 to 2023), and (3) data-driven platform optimization (2024). Modifications were made through qualitative learner and user surveys, crowdsourced cases to guide implementation, and quantitative data metrics. A matched prepost methodology for testing was used for learners, and a key outcome measure was impact on mastery defined as correctness and confidence for scenario-based questions. Results Symposia-based education significantly improved provider knowledge, competence, and confidence for all learning domains except shared decision making and treatment selection. Based on learner data and qualitative provider feedback, a freely accessible web-based platform was launched (IBD CDST; www.CDSTforIBD.com). The platform had significant positive impacts on knowledge, competence, confidence, practice, and clinical decision-making learning domains, including shared decision-making. A greater than 200% increase in mastery was observed because of the educational platform model. The impact was consistent for physicians and advanced practice providers. Conclusions We have built a freely accessible web-based decision support tool platform for advanced medical therapy selection in IBD that significantly improved provider mastery in decision-making for advanced medical therapies.

Year:

2024

Background The Endoscopic Healing Index (EHI) is a serum biomarker panel that can predict endoscopic inflammation in Crohn’s disease (CD). Methods Paired serum samples with endoscopies from adult patients participating in a prospective biobank (June 2014 to December 2018) were analyzed post hoc. Diagnostic performance for EHI was assessed against the individual parameters of the Simple Endoscopic Score for CD using previously identified cutoffs. Confounders for EHI performance were identified using logistic regression. Results A total of 205 CD patients were included (50% male, median age 37 years). An EHI of 20 points was sensitive for ruling out any ulcers (85%; 95% confidence interval [CI], 77%-91%) and large (5-20 mm) or very large (>20 mm) ulcers (93%; 95% CI, 84%-97%). An EHI of 50 points was specific for ruling in any ulcers (86%; 95% CI, 76%-92%) and large or very large ulcers (87%; 95% CI, 79%-92%). After accounting for total extent of inflamed mucosa, strictures, and disease location, each 20-point increase in EHI was associated with a 1.7-fold increased probability for the presence of large or very large ulcers (adjusted odds ratio, 1.7; 95% CI, 1.1-2.6). Conclusions The EHI was independently associated with ulcer size and accurately identified large or very large ulcers. A cutoff of 50 points can reliably rule in mucosal ulcers and allow for treatment adjustment. A cutoff of 20 points can reliably rule out mucosal ulcers and signal completion of treatment adjustment algorithms.

Year:

2022

Collaborators (11)

Walter Reinisch

Medical University of Vienna

AUSTRIA
View details

Rikkert Nap

Northwestern University

UNITED STATES
View details

Taku Kobayashi

Kitasato University

JAPAN
View details

Yuan Luo

Chief AI Officer and Associate Professor

Northwestern University

UNITED STATES
View details

Remo Panaccione

Director, Inflammatory Bowel disease Unit, Professor of Medicine

University of Calgary

CANADA
View details

Chengsheng Mao

Research Assistant Professor

Northwestern University

UNITED STATES
View details

Kyle MacQuarrie

Assistant Professor

Lurie Children's Hospital

UNITED STATES
View details

Britta Siegmund

-

GERMANY
View details

Zexian Zeng

Peking University

CHINA
View details

Neeraj Narula

-

CANADA
View details

Yawei Li

Research Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details